ALLR

Allarity Therapeutics, Inc.
CAPPED RATING

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Allarity Therapeutics, Inc. (ALLR) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D-). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.8 / 5.0
Growth
D-
Factor Score 0.8 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.0
EV / EBITDA -1.9
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -35.2%
Price Return 12M -26.5%
Catalyst Signal 0.00
Market Cap $13.9M
TTM Revenue $345.0K
Price / Sales 40.4
ROE -157.1%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.8) D- (0.8) C- (2.1) D+ (1.6) C+ (2.6) C- (2.0)
2026-11-10 C+ (2.7) D- (0.8) C- (2.1) D+ (1.6) C+ (2.6) C- (2.0)
2026-11-03 C+ (2.7) D- (0.8) C- (2.1) C- (2.1) C+ (2.7) C- (2.1)
2026-10-27 C+ (2.8) D- (0.8) C- (2.0) D+ (1.8) C+ (2.6) C- (2.0)
2026-10-20 C+ (2.8) D- (0.8) C- (2.0) C- (2.1) C+ (2.6) C- (2.1)
Page 1 of 4